Hyperthermia represents a unique, safe, and advantageous methodology for improving therapeutic strategies in the management of bladder cancer. This modality has shown promise in contributing to treatment regimens for both superficial and muscle-invasive disease. Especially in conjunction with intravesical chemotherapy, systemic therapy, and radiotherapy, hyperthermia shows particular synergistic benefit. As such, it should be explored further through clinical use and clinical trial in conjunction with currently available techniques and emerging technologies. However, to conceptualise the way forward, it is particularly important to understand the current challenges to widespread use of non-invasive, bladder-sparing approaches and the current state of bladder cancer care. As such, in the following article, we have focused on not only the rationale for concurrent radiotherapy and hyperthermia, but also the clinical landscape in bladder cancer as a whole.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2016 Apr 20 [Epub ahead of print]
James William Snider, Niloy Ranjan Datta, Zeljko Vujaskovic
a Department of Radiation Oncology , University of Maryland Medical Center , Baltimore , Maryland , USA ;, b Department of Radiation Oncology, KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland., a Department of Radiation Oncology , University of Maryland Medical Center , Baltimore , Maryland , USA ;